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and Surfactants
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Abstract
Nanostructured materials require evaluation at a molecular level to become 
controllable and useful in drug and vaccine delivery. Over the years self-assembled 
nanomaterials such as nanoparticles and thin films have been prepared, character-
ized and used for biomedical applications. In this review meaningful examples of 
biomimetic nanomaterials and their construction based on intermolecular interac-
tions such as the electrostatic attraction or the hydrophobic effect will be discussed. 
Emphasis will be placed on the interactions between polymers, lipids, surfactants 
and surfaces leading to bioactive supramolecular assemblies such as nanoparticles 
and coatings. Among the important applications of the self-assembled nanostruc-
tures and films to be reviewed are their antimicrobial effect and their adjuvant 
activity for vaccine delivery.
Keywords: lipid polymer nanoparticles, antimicrobial nanostructures,  
adjuvants for vaccines, intermolecular interactions, assembly and disassembly
1. Introduction
Life is ephemeral as are the assemblies that make life possible. Among the 
nanomaterials, the biomimetic nanomaterials mimic the assemblies found in living 
creatures and may find a myriad of useful applications [1–9]. The bioactive biomi-
metic nanomaterials encompass a wide variety of hybrid metastable nanostructures 
keeping different or similar molecules transiently together thanks to weak but 
frequent intermolecular interactions as are the van der Waals, the hydrogen bridges, 
the electrostatic and electrodynamic interactions, and the hydrophobic effect  
[10, 11]. Among these, one may say that the lipid polymer, the lipid inorganic 
materials and the coatings with NPs inclusion have been the subject of important 
developments in drug and vaccine delivery to fight pathogens and prevent, treat 
or diagnose major human diseases such as cancer. Stimuli responsive assemblies 
with the use of various triggers such as pH, temperature, light, enzyme, and redox 
potential are emerging strategies for the effective localization of the bioactives at 
the tumor site for safe and effective cancer therapy or diagnosis despite all problems 
with multidrug resistance, long-lasting chemotherapy and low transfection and 
non-specific immuneresponse after systemic delivery of siRNa [12]. For example, 
a biomimetic phospholipid-like amphiphilic prodrug, 1-O-octodecyl-2-conjugated 
linoleoyl-sn-glycero-3-phosphatidyl gemcitabine (OLGPG) combined with choles-
teryl hemisuccinate polyethylene glycol 1500 (CHS-PEG) upon injection in water 
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formed the OLGPG and OLGPG/CHS-PEG nanometric spherical vesicles due to the 
hydrophobic interaction of lipid moieties. Since phospholipase A2 (PLA2) is highly 
expressed in tumor tissues and specifically degrades the 2-acyl of the phospholipids to 
lysophospholipids, a PLA2-sensitive OLGPG specific degradation in the tumor tissue 
was obtained [13]. In this same work, the in vivo experiments with a hepatocellular 
tumor-bearing mouse model showed that these long-circulating phospholipid-like 
prodrug nanoassemblies yielded the highest antitumor and tumor targeting effects 
compared to the other groups [13].
Today (30 November 2018) a search of the literature on lipid polymer coatings 
in the Scopus database produced 26,123 items whereas a search on lipid polymer 
nanoparticles resulted in 24,042 publications. I feel somewhat proud to have wit-
nessed and contributed to some of the early and late developments on lipid polymer 
[14–23] and lipid silica NPs [24–29] that started about 3 decades ago. In particular, 
cationic lipids by themselves or in combination with other lipids or assemblies can 
yield interesting microenvironments to accommodate a variety of bioactive mol-
ecules such as drugs, antigens, peptides, nucleic acids, etc. [30–37]. The nanometric 
size and positive charge impart desirable properties for the cationic assemblies 
after injection via parenteral route in vivo. Good instances are the direct action at 
the lymph nodes for stimulation of dendritic cells for vaccines [9, 22, 31, 34–37], 
and the penetration of nasal mucosae to overcome the blood brain barrier releasing 
drugs into the brain [33]. Other important applications relate to the antimicrobial 
properties of a variety of cationic assemblies either by themselves such as cationic 
bilayers or in effective combinations with other antimicrobials such as antibiotics, 
polymers or peptides [7, 23, 38–45].
This review will discuss mostly seminal and recent contributions regarding 
applications of biomimetic nanoparticles and coatings in antimicrobial therapy 
and vaccine development. Emphasis will be placed on lipid polymer NPs and their 
coatings plus their biomedical applications in drug and vaccine delivery.
2. Lipid polymer nanoparticles: overview on their applications
Lipids and polymers have been yielding a myriad of combinations. From 
the 24,042 publications on lipid polymer nanoparticles found today, 6173 were 
review articles. Many of them referred to solid lipid nanoparticles or nano-
structured lipid carriers and the associated problems regarding drug location 
and arrangements of the lipids and the stabilizing agents in the lipid particle 
nanostructure [46, 47]. These NPs are based on lipid cores stabilized by layers 
of hydrophilic polymers [48, 49]. They may also assume the form of nanodiscs 
or open bilayer fragments (BF) [17]. The scaffold is then an organized and 
open lipid bilayer disk of charged and saturated synthetic lipids [50, 51] or 
compositions containing polyethylene glycol covalently bound to lipids [52]. 
Dioctadecyldimethylammonium bromide bilayer fragments (DODAB BF) with 
two consecutively deposited layers of carboxymethylcellulose (CMC) and polyd-
iallyldimethylammonium chloride (PDDA), respectively, were effective microbi-
cidal assemblies [39, 40]. This activity was associated with the outermost layer of 
the cationic antimicrobial polymer PDDA [39–41]. The visualization of the lipid 
or lipid polymer nanodiscs was achieved by advanced microscopy techniques 
such as shown from cryo-transmission electron micrographs (cryo-TEM) [52] in 
Figure 1(a), transmission electron micrographs with electronic staining of the 
nanodiscs in Figure 1(b) or scanning electron micrographs of the DODAB BF/
CMC/PDDA nanodiscs in Figure 1(c). It is interesting to notice that the disks 
could be observed both face-on and edge-on.
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Dispersions of phospholipids such as 1,2-dimyristoyl-sn-glycero-3-phosphocholine  
(DMPC) and 1,2-dihexanoyl-sn-glycero-3-phophocholine (DHPC) can yield also 
discoidal and open lipid particles; the short-chain components preferentially occupy 
curved rim environments around bilayer disks of the long-chain components [53, 
54]. Cationic peptides such as a lung surfactant protein and the antimicrobial 
peptide magainin 2 interacted with the DMPC/DHPC neutral bicelles but did not 
affect their structure as seen from magnetic resonance spectroscopy [53]; for disks 
containing the anionic 1,2-dimyristoyl-sn-glycero-3-phopho-(1′-rac-glycerol) 
(DMPG) the peptides lowered the temperature at which the particles coalesced into 
more extended lamellar structures or promoted partitioning of the zwitterionic and 
anionic long-chain lipid components into different environments [53].
Other lipid–polymer hybrid nanoparticles consist of a polymer core surrounded 
by a lipid shell combining properties of both polymeric nanoparticles and lipo-
somes and often referred to as biomimetic nanoparticles [14–23, 55–58]. Sometimes, 
when the lipid has good affinity for the polymer, it can be embedded in the poly-
mer matrix as was the case of the cationic lipid dioctadecyl dimethyl ammonium 
bromide (DODAB) and poly methyl methacrylate (PMMA) polymer for producing 
microbicidal PMMA/DODAB coatings from spin-coating [59]. In these coatings 
the cationic lipid DODAB accounted for the microbicidal activity [59]. Hadinoto 
and co-workers reviewed the literature on lipid-coated polymeric nanoparticles 
Figure 1. 
Micrographs and some schemes of cross sections for discoidal NPs made of lipid bilayer disks or fragments 
without (a, b) or with outer layers of polymers (c). On (a), the cryo -TEM of DODAB BF (bar is 100 nm). 
Adapted from [50] with permission from 1995 American Chemical Society. On (b), negatively stained 
anionic sodium dihexadecylphosphate (DHP) BF seen from TEM (bar is 100 nm). Adapted from [51] with 
permission from 1991 American Chemical Society. On (c), scanning electron micrograph of microbicidal 
discoidal NPs where DODAB BF supported consecutive polymer layers of carboxymethylcellulose (CMC) and 
polydiallyldimethylammonium chloride (PDDA) [41].
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(LPNPs) prepared from natural polymers such as chitosan (CS) and the biocompat-
ible and biodegradable poly-lactic-co-glycolic acid (PLGA), and their applications 
as a delivery platform for cancer therapy [60].
Leaf Huang and co-workers recently gave a comprehensive account on the 
important role of lipid polymer nanoparticles in combination therapy against 
cancer including chemotherapy, photodynamic therapy, thermal heating treatments 
with metals, siRNA delivery and others [61]. Some synergistic combinations of 
anti-cancer drugs can circumvent resistance to treatment and be effective in anti-
cancer therapy. For example,
NPs formulated through self-assembly of the biodegradable PLGA and a 
cationic, hydrophobic molecule carried siRNA to knock down target oncogenes 
and to deliver cisplatin prodrug to tumors both in vitro and in vivo [62]. The NPs 
induced a significant and sustained suppression of genes in a human lymph node 
carcinoma of the prostate xenograft mouse model for up to 3 days after a single 
dose. Administering these NPs revealed a synergistic effect on tumor inhibition that 
was strikingly more effective than cisplatin monotherapy [62]. On reference [62] 
the cationic molecule was embedded in the PLGA-PEG shell and the cargo of siRNA 
was in the inner aqueous core.
Messerschmidt and coworkers [63] described another sophisticated system of 
lipid polymer NPs aiming at cancer combined therapy. Lipid coated -polystyrene 
NPs endowed with several functions such as targeting to the cancer cells with a 
single-chain Fv antibody fragment, steric stabilization of the outer lipid layer with 
polyethylene glycol (PEG) lipids and single chain tumor necrosis factor (scTNF) 
covalently bound to the polystyrene core [63]. Thereby, the system specifically 
delivered scTNF to the cancer cells inducing their death by apoptosis without 
affecting the healthy cells.
Many applications in drug and vaccine delivery for the hybrid polymer lipid NPs 
called biomimetic nanoparticles were systematically reviewed over the last three 
decades [7, 8, 17–19, 31, 38, 44, 55–58, 64–66]. In special when either the lipid or 
the polymer is cationic, lipid polymer NPs display remarkable interactive capability 
with bioactive molecules and can impart antimicrobial properties to a variety of 
nanomaterials adding functionality to dispersions, surfaces and coatings and allow-
ing to obtain interesting combinations of bioactive molecules and assemblies. Novel 
approaches proliferate exponentially for the development of different advanced 
materials shaped as NPs, hydrogels and surface coatings with effective antimicro-
bial properties. Bassegoda and coworkers recently gave a comprehensive account 
on major strategies to prevent the occurrence of resistance against antibiotics by 
using advanced materials [67]. Advanced materials occur as anti-fouling molecules 
and surfaces that prevent microorganisms adhesion and formation of biofilms or 
they are bactericidal materials that cause cell membrane disruption, production of 
reactive oxygen species with damage to vital biomolecules in the cell or materials 
that damage vital proteins [67]. They recognized the importance of antimicrobial 
biomimetics from the need of a new generation of hybrid materials with strong 
antimicrobial/antifouling activities and improved biocompatibility imparted by 
“safety design” [67]. In the next section we discuss some of these cationic materials.
3.  Cationic lipid polymer nanoparticles, coatings and applications in 
antimicrobial biomimetics and vaccine delivery
Cationic lipid polymer NPs and coatings are strategic for applications in 
antimicrobial biomimetics and vaccine design [7, 8, 38–45, 55–59]. Due to the 
cationic lipid, lipid polymer cationic NPs can combine effectively with antibiotics 
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like amphotericin B or miconazole [39, 68–70], rifampicin [71], clarithromycin 
[72], anti-inflammatory hydrophobic drugs like indomethacin [32], nucleic acids 
[21], oligonucleotides [35, 73, 74], proteins in general including serum proteins, 
transmembrane proteins, receptors and toxins [75–78], antigens [9, 20, 22, 34–37], 
peptides [23, 43–45] or polymers [79, 80].
Early work on the affinity between the biocompatible PMMA polymer and the 
antimicrobial DODAB lipid showed that thin films of PMMA/DODAB casted by 
spin-coating a chloroformic solution onto silicon wafers were homogeneous and 
retained the microbicidal activity of DODAB [59]. Figure 2 illustrates the polymer 
lipid coatings of polystyrene (PS)/DODAB and PMMA/DODAB; whereas DODAB 
did not mix homogeneously with PS (Figure 2(a), the film resulting from the 
PMMA/DODAB spin-coating procedure in Figure 2(c) was very smooth and homo-
geneous as reproduced from reference [59]. The live-dead testing for Escherichia coli 
showed green, and alive bacteria on the PMMA coating (Figure 2(e) and red, and 
dead ones on the PMMA/DODAB coating (Figure 2(f)).
Taking advantage of the good compatibility between DODAB lipid and PMMA, 
Melo and co-workers evaluated the interaction between different quaternary 
ammonium surfactants and PMMA from spin-coated PMMA/DODAB and PMMA/
CTAB films on silicon wafers or glass coverslips [81]. The mobility of CTAB in the 
coatings allowed this surfactant to leak to the outer medium in contrast with the 
permanence of DODAB in the coatings and its antimicrobial action by contact [81].
In another meaningful instance, Naves and co-workers synthesized PMMA NPs 
by emulsion polymerization in the presence of DODAB or CTAB and determined 
the antimicrobial activity of the dispersions [82]. Loading the biocompatible poly 
acrylic particles with the quaternary ammonium surfactants was a facile, fast, 
low-cost approach to obtaining highly efficient antimicrobial nanoparticles which 
either killed by contact in the case of embedded DODAB or by leakage to the outer 
medium in the case of CTAB [82].
The biocompatible PMMA polymer and the antimicrobial and cationic polymer 
PDDA reunited by synthesizing PMMA in the presence of PDDA yielded interesting 
Figure 2. 
Optical microscopy of hybrid polymer-DODAB films obtained by spin-coating: (a) PS-DODAB;  
(b) PS-DODAB rinsed with ethanol; (c) PMMA-DODAB; (d) PMMA-DODAB rinsed with ethanol; (e) E. coli 
on PMMA film; (f) E. coli on PMMA/DODAB film. Adapted from reference [59].
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NPs [83]. This was a facile alternative approach in comparison to strategies based on 
the synthesis of block copolymers incorporating both functions. Figure 3 shows the 
macroscopic and microscopic appearance of the very stable dispersions of PMMA/
PDDA and PMMA/PDDA/cationic amphiphile and some of their films obtained 
Figure 3. 
Stable NPs dispersions of biocompatible polymer (PMMA), antimicrobial polymer (PDDA) and cationic lipid 
(DODAB) or surfactant (CTAB) in form of NPs dispersions in water just after synthesis (a) and 6 months 
after synthesis (b). Coatings were obtained by casting and drying NPs water dispersions on polystyrene, silicon 
wafer or glass coverslip surfaces from left to right (c). The SEM micrograph for the PMMA/PDDA NPs 
coatings showed the NPs film obtained after drying (d). Reproduced from reference [80].
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by casting and drying the water dispersions of NPs onto different surfaces such as 
polystyrene, silicon wafers or glass coverslips [80].
Against fungus such as Candida albicans, the variable antimicrobial activity of 
the quaternary ammonium nitrogen in lipids, surfactants and polymers was previ-
ously established by our group [40, 84–86]. While substantial fungicidal activity 
was described for the micelle-forming CTAB surfactant, the bilayer–forming  
DODAB did not show the ability of moving from the bilayer assembly to the fungus 
cell membrane [85]. As a consequence a poor fungicidal activity of DODAB bilay-
ers assembled as bilayer fragments or as large vesicles was obtained [84, 86]. The 
microbicidal quaternary nitrogen only kills the fungus if its host molecule has 
mobility enough to cross the thick and dense layer of glycoproteins at the outer 
fungus cell wall. Adsorption isotherms of CTAB and DODAB on C. albicans were 
revealing; increasing DODAB concentration reduced its adsorption onto the cells 
due to the preferential vesicle-vesicle instead of the vesicle-cell interaction [87]. In 
contrast to other surfactants such as sodium dodecyl sulfate (SDS), CTAB did not 
disrupt the cell membrane and cell death occurred when the cell became positively 
charged [85]. Fungus death requires adsorption of the quaternary ammonium 
moiety to the cell, change in the cell charge and penetration through the cell wall 
reaching the fungus cell membrane. Since DODAB, in the DODAB bilayer, exists 
mostly in the rigid gel state there is no penetration of the quaternary ammonium 
moiety into the fungus cell wall and cytoplasmic membrane what explains the poor 
DODAB activity against fungus when compared to other micelle-forming surfac-
tants [84, 85]. These considerations directly lead to the prediction that mobile poly-
mers bearing the quaternary ammonium moiety would be efficient antimicrobial 
agents against fungus. Polymer immobilization, however, would reduce their action 
and these were indeed the experimental results [40, 83]. Immobilization of PDDA 
in PMMA/PDDA NPs substantially reduced the PDDA fungicidal action against 
C. albicans [83]. PDDA by itself showed remarkable fungicidal activity (minimal 
fungicidal concentration of 0.5 μg/mL) in complete absence of toxicity against red 
blood cells [86]. Very recently, Fait and co-workers comprehensively revised the 
structure–function activity of cationic surfactants as antifungal agents [88].
For vaccines, cationic nanostructures have been revealing their potential in 
several instances from combinations with cationic lipids or other hybrid assemblies 
shaped as microparticles or nanoparticles [7–9, 17–22, 28, 31, 34–37, 55, 58, 64, 
66, 76, 78]. The possibility of varying sizes from nanometric to micrometric and 
the positive charge are major assets for adjuvants since they allow combinations 
with the vast majority of antigens such as proteins, peptides, haptens, nucleic 
acids, oligonucleotides or other negatively charged biological combinations such as 
extracts of pathogens. The nanosize is valuable for localizing the antigen directly 
in the lymph nodes where capture by antigen presenting cells may elicit suitable 
humoral and cellular defenses. Manolova and co-workers showed that particles tar-
get distinct dendritic cell populations according to their size [89]. Virus-sized NPs 
with 20–200 nm diameter are captured by dendritic cells (DC) whereas bacteria 
with 500–5000 nm diameter are captured by phagocytes or macrophages. Whereas 
images of large particles (500–2000 nm) localized them in DC from the injection 
site, small (20–200 nm) NPs and virus-like particles (30 nm) were also found in 
lymph nodes-resident DC and macrophages, suggesting free drainage of NPs to 
the lymph nodes; particle size determined the mechanism of trafficking to the LN 
so that only small NPs could specifically target LN-resident cells [89]. Manolova 
and co-workers [89] considered the mechanism of NPs trafficking from the skin to 
the draining LN in vivo; the optimal size for lymphatic uptake would be between 
10 and 100 nm [89]. The initial lymphatic vessels are lined with overlapping 
endothelial cells so that DC and fluids from the interstitial space enter lymphatic 
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vessels through the endothelial cell junctions. Hence, these junctions might act as 
a molecular sieve and could prevent large particles from entering freely into the 
afferent lymphatics [89]. In the interstitial space, DC that captured large particles 
would carry them into the lymphatics. In addition, large particles would remain 
more tightly trapped in the interstitial space before entering the lymphatics. Their 
prolonged residence in the interstitium would increase the probability of phagocy-
tosis. The role of NP charge was reviewed [90] and the boosting of cationic NPs for 
generating antigen-specific CD4(+) T cell proliferation was demonstrated [91].
4. Conclusions
The plethora of biomolecules that can be combined with polymers enables the 
design of new types of polymer-based NPs and interfaces, for example antimicro-
bial coatings from hybrid lipid polymer NPs [80, 83], possibly useful in medical 
devices, which will hopefully provide innovative preventive and therapeutic 
approaches in medicine.
Future generations of biomimetic systems will involve more complex composi-
tions and combinations, leading to insights into fighting pathological conditions. 
Future developments in biomimetic assemblies including polymers will certainly 
improve and expand biomedical applications and significantly advance the treat-
ment of cancer and many other diseases.
Nowadays lipid polymer, positively charged, biomimetic NPs are available over 
a range of sizes for vaccines design and drug delivery. Biomimetic lipid polymer 
NPs were first described by our group in the nineties [7–9, 14–16, 92]. The last 
decades witnessed significant extensions in our repertoire so that lipid-polymer and 
polymer-lipid dispersions or coatings, nanosized bilayer fragments, bilayer-covered 
polymeric particles, and layer-by-layer lipid polymer assemblies, most of them 
cationic, found novel applications as adjuvants for vaccines, as carriers for drug 
delivery and as antimicrobial assemblies.
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